{"disease":{"id":"long-chain-fatty-acid-oxidation-disorders-lc-faod","name":"long chain fatty acid oxidation disorders lc faod"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01886378","title":"A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":true},{"nct_id":"NCT03768817","title":"Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":false},{"nct_id":"NCT04812106","title":"Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program","phase":"","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}